STAT3 and benign prostatic hyperplasia: Similarly, in Fig. 5C, p-STAT3/t-STAT3 levels were significantly elevated in the BPH group, whereas both HCQ and FIN treatments effectively reduced phosphorylation levels, with the combination showing the strongest inhibitory effect (p < 0.0001).